A Dose-finding Trial of Hyperthermic Intraperitoneal Docetaxel
Status:
Recruiting
Trial end date:
2023-02-01
Target enrollment:
Participant gender:
Summary
This is a single-center study design, and 30 patients will be enrolled. Eligible patients
will receive docetaxel at different dose levels according to the trial schedule.All the
enrolled patients were treated with docetaxel during the first HIPEC treatment and cisplatin
during the second HIPEC treatment at 43℃ for 1 hour.The dose of docetaxel for patients in the
next group was determined according to the incidence of dose-limiting toxicity (DLT) of the
previous docetaxel dose level. Finally, the maximum tolerated dose (MTD) of docetaxel for
HIPEC was calculated according to the incidence of dose-limiting toxicity.
Phase:
Phase 1
Details
Lead Sponsor:
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University